Skip to Content

Epcoritamab (epcoritamab-bysp) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

Download PQI pdf 0.31MB

Last Updated: April 14, 2025

By: Syed Zia Khan, PharmD, BCSCP

About this PQI

The purpose of this PQI is to discuss the clinical considerations of epcoritamab-bysp (Epcoritamab®) to optimize the outcomes for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI